SCHEMBL1103575

SCHEMBL1103575

c1ccc2c(-c3ccc4cc(-c5c6ccccc6c(-c6cccc7ccccc67)c6c5cnc5ccccc56)ccc4c3)cccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.46
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
CYP2B6 P20813 1/20 0.37
CYP2C19 P33261 1/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
RECQL P46063 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ERN1 O75460 1/20 0.37
KDM4E B2RXH2 2/20 0.36
GPR3 P46089 1/20 0.36
PIM1 P11309 1/20 0.36
CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103453 0.97 MET (0.42) METCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1103367 0.96 MET (0.46) METCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1103526 0.95 MET (0.48) METCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1103580 0.95 MET (0.43) METCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1103578 0.94 MET (0.47) METCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1103388 0.93 MET (0.44) METCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1103579 0.93 MAPT (0.41) METCYP11B1CYP11B2NPC1LMNA
SCHEMBL1103457 0.93 ESR1 (0.42) METNPC1LMNAMAPTRECQL
SCHEMBL1103566 0.93 MET (0.42) METCYP11B1CYP11B2NPC1LMNA
SCHEMBL1103516 0.93 MET (0.47) METCYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 MET 4191/4885CYP1A2 1437/4885CYP3A4 1409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.